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1887, Noccard-Mollereau, bovine mastitis 
1933, Group B Antigen  
1964, severe neonatal sepsis 
Ø 1970,	  N°1	  in	  neonatal	  infecMons	  
Gram positive cocci  
 Catalase - 
 β-hemolytic 
 CAMP test + 
 Hippurate + 
 Esculine- 
 Orange pigment 
	  
10 capsular serotypes (Ia, Ib, II-IX)  
	  
Streptococcus agalactiae or GBS 
Rebecca Lancefield	
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Group B streptococcal diseases in 
neonates 
§  Since the 1970s, leading cause of life-
threatening infections in newborns 
§  Neonatal illness/death 
§  Long-term disabilities 
§  Maternal morbidity  
§  Along pregnancy  
§  Peripartum 
§  Serious diseases among elderly and adults with 
underlying diseases 
§  Significant mortality 
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GBS Neonatal Infections  
A. Schuchat, Clin Microb Rev 1998;11:497-513 
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80 % EOD	

EOD : 80-90 % occur  




GBS Neonatal Infections 	  
A. Schuchat, Clin Microb Rev 1998;11:497-513 
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EARLY Onset LATE Onset 
Incidence 0.5 - 4,7 per 1000! 0.3 - 1,8 per 1000!
Onset <  6 days of live!
                                  (X : 1 - 10 h)!
> 6 days of live   




            At delivery         
Nosocomial 
 In the community 
Clinical signs Respiratory distress!
with pneumonia!
Sepsis!





Mortality 5 – 10% 0-6% 
Sequelae  When meningitis : neurological sequelae!
Pulmonary weakness 
Serotypes All  (III, Ia & V) ! III, mainly!
(Meningitis & Clone ST-17)!
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Burden of neonatal  GBS early onset 
diseases in European countries 




Spain 2 (1996) to 0.45 
(2008)  
Lopez Sastre et al. 
Acta Pediatr 2005 
Belgium 2 Melin, Indian J Med 
Res 2004 
Eastern Europe 0.2 - 4 Trijbels-Smeulders, 
Pediatr Infect Dis J 
2004 Western Europe 0.3 - 2 
The Netherlands  1.9 
Scandinavia 0.76 - 2 
Southern Europe 0.57 - 2 
Data assessing more accurately the true burden are needed 
 
-  Carriage rate ? 
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40 - 60 %!60 - 40 %!
GBS EOD vertical transmission 
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40 - 60 %!60 - 40 %!
96	  -­‐	  98	  %	  
AsymptomaMc	  
GBS	  EOD	  verMcal	  transmission	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40 - 60 %!
2 - 4 %!
GBS EOD 
60 - 40 %!









GBS	  EOD	  verMcal	  transmission	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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 










-  C5a peptidase 
-  ….. Bacteria 
Peptidoglycan 
β-hemolysin, … 
IL1, IL6, TNF α, 
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GBS maternal colonization 
Risk factor for early-onset disease (EOD) : 
vaginal GBS colonization at delivery 
 
§  GBS carriers  
§  10 - 35 % of women 
§  Clinical signs not predictive 
§  Dynamic condition 
§  Intestinal reservoir 
§  Prenatal cultures late in pregnancy can predict 
delivery status 
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Additional Risk Factors  
for Early-Onset GBS Disease 
  Obstetric factors:  
  Prolonged rupture of  
membranes,  
  Preterm delivery,  
  Intrapartum fever 
  GBS bacteriuria 
  Previous infant with GBS disease 
  Immunologic:  
  Low specific IgG to GBS capsular 
polysaccharide 
No difference in occurrence either in GBS 
Positive or Negative women, except 
intrapartum fever 
Lorquet S., Melin P. & al. 	
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GBS EOD - Belgian data 
§  Incidence 
§  1985 -1990: 3/1000 live births 
§  1999, estimation : 2/1000 live births 
§  2010, estimation : < 1/1000 live births  
§  Meningitis : 10 % 
§  Mortality : 5 -10 % 
§  60 % EOD (130 cases) : WITHOUT any maternal/
obstetric risk factor except colonization 
§  Prenatal screening 
§  Recto-vaginal cultures : 13-35 % GBS Positive 
P. Melin -  2001, 2007 - Reference laboratory for GBS.	
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EUROPEAN DATA 
Data from DEVANI Project  (2008-2011)  
Belgium – Bulgaria – Czech Republic – Denmark – Germany – Italy – Spain – 
United Kingdom  
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Mothers of newborns with EOD 
(Devani, 2008-2010 Europe) 
PW Screened in prenatal care 
 
                             Cases’ mothers   GBS positive Control  
    (mothers of healthy babies) 
§  Vagino-rectal swab       24%     
§  IAP if GBS positive       41%   84% 
Notified risk factors for EOD 
§  ROM >18h       24.8%    5% 
§  T° >= 38°C       14.3%   1% 
§  GBS Bacteriuria       8.5%   3.9% 
§  Previous GBS sibling      0.9%   0.3% 
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Distribution of CPS serotypes among 
GBS from neonatal infections  
(Devani, 2008-2010 Europe) 
Type	  III	  :	  
	  82%	  LOD	  
	  43%	  EOD	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GUIDELINES 
	  	  	  	  GUIDELINES 
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Which prevention 
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Prevention of perinatal GBS EOD	  
§  Intrapartum antibiotics 
§  Highly effective at 
preventing EOD in 
women at risk of 
transmitting GBS to 
their newborns ( > 4 h) 
(clinical trials in late 80s) 
Who is  
the women  
at risk ? 
Risk-based strategy  
or 
Screening-based strategy 
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Prevention of perinatal GBS EOD	  




Main goal :  
§  To prevent 70 to 80 % of GBS EO cases 
Secondary : 
§  To reduce peripartum maternal morbidity 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases in 
the 1990s, U.S. 
   Consensus   
   guidelines: 
- Screening  
-Risk-based 
Group B Strep 
Association 
formed  
  1st ACOG & AAP 
   statements 
           CDC draft  
guidelines published 
S. Schrag, New Engl J Med 2000 
Schrag S. et al. N Engl J Med 2002; 347:233-9 
 
Screening >50%  
more effective  
than RF 
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Why is Screening more protective 
than the risk-based approach ? 
Schrag	  S.	  et	  al.	  N	  Engl	  J	  Med	  2002;	  347:233-­‐9	  
Broader coverage of « at-risk » population 
Ø  Captures colonized women without obstetric RF 
Ø  High level of compliance with recommendations 
Ø  Enhanced compliance with risk-based approach 
cannot prevent as many cases as universal 
screening 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases, U.S. 
Incidence of early- and late-onset invasive group B streptococcal disease in 















































	  	  	  	  GUIDELINES 
27	  	  	  	  	  	  	  	  INTRODUCTION	  &	  BURDEN	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GUIDELINES	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SCREENING	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  VACCINE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CONCLUSION	  ESPID	  10.05.2012	  
CDC, USA, MMWR, Vol 59 
(RR-10) August 2010 
Endorsed by 
  - AAP  
  - ACOG 
 
            SHC, Belgium July 2003 
Revision ongoing 
department of health and human services
Centers for Disease Control and Prevention
Recommendations and Reports November 19, 2010 / Vol. 59 / No. RR-10
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Prevention of Perinatal Group B 
Streptococcal Disease
Revised Guidelines from CDC, 2010
Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html
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European strategies 
for prevention of GBS EOD 
§  Intrapartum antibioprophylaxis recommended 
§  Screening-based strategy 
§  Spain, 1998, 2003, revised 2012 
§  France, 2001 
§  Belgium, 2003, revision ongoing 2012 
§  Germany, 1996, revised 2008 
§  Switzerland, 2007  
§  Risk-based strategy 
§  UK, the Netherlands, Denmark 
§  No guidelines 
§  Bulgaria, … 
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Universal screening-based strategy for 
prevention of GBS perinatal disease 
Vagino-rectal GBS screening culture  at 35-37 weeks of gestation  
 
For ALL pregnant women 
> 1 Risk factor:  
   - Intrapartum fever > 38°C*** 
   -  ROM > 18 hrs 




























if NO! if YES!
Unless patient had a previous infant with GBS invasive disease  
 or GBS bacteriuria during current pregnacy 
 or delivery occurs < 37 weeks’ gestation * 
GBS Neg 
if  YES!
GBS POS Not done, incomplete or 
unknown GBS result 
! Facultative !  
Intrapartum rapid GBS  test** 
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Intrapartum IV Antibio-Prophylaxis 
(CDC 2010, Belgian SHC 2003)	  
§  Penicillin G 
§  5 millions U, IV initial dose, then 2,5 to 3 millions U IV every 4 
hours until delivery. 
§  Ampicilline   
§  2 g IV initial dose, then 1 g IV everye 4 h until delivery. 
§  Acceptable alternative , but broader spectrum, potential selection of R 
bacteria 
§  If penicillin allergy 
§  Patients at low risk for anaphylaxis 
§  Cefazolin, 2 g IV initial dose, then 1g IV every 8 h until delivery.  
§  Patients at high risk for anaphylaxis  
§  Clindamycin, 900 mg IV every 8 hours until delivery. 
§  If GBS resistant to clindamycin : use vancomycin 
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Concerns about potential adverse / 
unintended consequences of prophylaxis 
§  Allergies   
§  Anaphylaxis occurs but extremely rare 
§  Changes in incidence or resistance of other 
pathogens causing EOD 
§  Data are complex … 
§  BUT Most studies: stable rates of « other » sepsis 
§  Changes in GBS antimicrobial resistance  
profile 
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Concerns : Clinically relevant 
antimicrobial resistance 
§  Increase of resistance to erythromycin and 
clindamycin 
§  Susceptibility to penicillin 
§  Very few « not S » isolates recently characterized 
in Japan  
§  Mutation in pbp genes, especially pbp2x  
§  MIC= 0.25 -1 mg/L 
§  No clinical impact ? 
Noriyuki Nagano et al, AAC 2008	

§  Very few in the U.S. 
§  All labs should send to reference lab 
§  Any « non-S » isolate for confirmation 
§  All invasive isolates for resistance surveillance 
	  	  	  	  GUIDELINES 
35	  	  	  	  	  	  	  	  INTRODUCTION	  &	  BURDEN	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GUIDELINES	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SCREENING	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  VACCINE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CONCLUSION	  ESPID	  10.05.2012	  
Erythromycin and clindamycin 
resistance	  
Erythromycin R 
§  USA, 15-35% 
§  Ireland, 15-20% 
§  Europe, 10-30% 
§  Belgium, 32% 
GBS isolated in Belgium, from invasive 
diseases 
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Concerns about potential adverse / 
unintended consequences of prophylaxis 
§  Management of neonates 
§  Increase of unecessary evaluation 
§  Increase of unecessary antimicrobial treatments 
à Algorithm for secondary prevention of EOD 
among newborns 
§  Symptoms; maternal chorioamnionitis; 
prophylaxis; gestational age; time of rupture of 
membrane 
Rem.:  
80-90 % of GBS EOD are symptomatic < 24 h of live 
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Remaining burden of GBS EOD 
Missed opportunities 
In spite of universal screening prevention 
strategy 
In spite the great progress 
 Cases still occur 
§  Among remaining cases of EOD 
§  Some may be preventable cases 
§  Missed opportunities for (appropriate) IAP 
§  False negative screening 
Van Dyke MK, Phares CR, Lynfield R et al. N Engl J Med 2009 
CDC revised guidelines 2010 
Poyart C, Reglier-Poupet H, Tazi et al. Emerg Infect Dis 2008 
DEVANI project, unpublished data 2011 
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SCREENING  
FOR GBS COLONIZATION 
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Antenatal GBS culture-based 
screening 
Goal of GBS screening 
To predict GBS vaginal (rectal) colonization at the 
time of delivery 
§ 	  Critical factors influencing accuracy 
§  Swabbed anatomic sites 
§  Timing of sampling 




§  Non-culture  
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From direct plating on blood agar 
Evolution of culture methods 	  
Use of selective enrichment broth 
§  To maximize the isolation of GBS 
§  To avoid overgrowth of other organisms 
 
Use of differential agar media 
Recommended by some European guidelines (+ CDC 2010) 
 
 1983, 1992                            2005       2007 
GRANADA 
(M.de la Rosa,JCM) 
Strepto B 
Select  
StreptoB ID  
Pigment-­‐based 	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chromogenic	  media	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Which agar or which combination? 
+/- Blood agar 
 
Workload - costs - extra-testing - non β-hemolytic  
GBS detection  to be considered 
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§  WHEN   35-37 weeks 
§  WHO  ALL the pregnant women 
§  Specimen   Vaginal + rectal swab(s) 
§  Collection  WITHOUT speculum 
§  Transport  Transport/collection device/condition 
 (non nutritive medium: Amies/Stuart or Granada 
 like tube) (type of swab)(Length and T°) 
§  Request form  To specify prenatal « GBS » 
 screening  
§  Laboratory procedure 
Crucial conditions to optimize 
SCREENING 
(CDC 2010 - Belgian SCH 2003) 
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Prenatal culture-based 
screening: Limiting factors 
§  Positive and negative predictive values 
§  False-negative results 
§  Failure of GBS culture  (oral ATB, feminine hygiene) 
or new acquisition 
§  Up to 1/3 of GBS positive women at time of delivery 
§  Continuing occurrence of EO GBS cases 
§  False-positive 
§  Unnecessary IAP 
Need for more accurate	  predictor	  of	  	  
intrapartum	  GBS	  vaginal	  colonizaMon	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Alternative to GBS prenatal 
screening: intrapartum screening 
Theranostic approach 
Turnaround time 







30-45 minutes, 24 hrs/7 d, robust 
Benitz et al. 1999, Pediatrics, Vol 183 (6) 
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Real Time PCR for intrapartum 
screening 
§  Advance in PCR techniques & development of 
platforms 
§  BD GeneOhmTM Strep B Assay (+/- 1 hr) (in laboratory) 
§  Xpert GBS, Cepheid (35-50 min) (can be performed as a POCT)  
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Real-­‐Mme	  PCR,	  very	  promising,	  but	  …	  
§  Still an expensive technology 
§  Cost effective ?  
§  Logistic 
§  24 hours 7 days 
§  In the lab? 
§  In the obstetrical department ? 
§  In combination with prenatal screening strategy ? 
§  CDC 2010 
§  No antimicrobial result  
§  In the future detection of R genes, but mixed microbiota ! 
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VACCINE 
	  	  	  	  VACCINE 
Prevention of GBS EOD and LOD 
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Background	  
§  Correlate between maternal low level off CPS 
type Ab at time of delivery and risk for 
development of GBS EOD  
Baker C et Kasper D, 1976, NEJM 
 
 Vaccine for pregnant women: 
 Likely the most effective, sustainable and cost 
effective approach 
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GBS Vaccines, since the 1980s   
Challenges 
Capsular polysaccharide vaccines 
§  10 serotypes 
§  Different distributions 
§  EOD, LOD, invasives infections in adults 
§  Geographically and along time 
§  Conjugated vaccines 
§  Multivalent vaccines Ia, Ib, III, V 
§  Clinical studies 
§  Immunogenicity 
§  Safety 
§  Efficacy: scheduled/ongoing 
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GBS Vaccines 
GBS Protein-based Vaccine 
§  Ag = Surface proteins 
§  Cross protection against different serotypes 
§  Better immunogenicity 
§  Humoral response T-cell dependent   
    = long lasting immunity 
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Protein-­‐based	  Vaccines	  
Protein  Protective Ab  associated serotypes 
  (in mouse) 
Alpha-like proteins   
    Alpha  Yes    Ia, Ib et II 
    Alp1      Ia 
    Rib  Yes    III 
    Alp2  Yes    V, VIII 
    Alp3  Yes    V, VIII 
Beta C protein  Yes    Ib 
C5a peptidase  Yes    All 
Sip (1999)  Yes    All 
BPS  Yes    All 
Sip = Surface Immunogenic Protein (Brodeur, Martin, Québec)  
BPS= Groupe B Protective surface Protein 
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Protein-based Vaccines 
Reverse vaccinology approach 
Knowledge of complete GBS genome 
 
§  Comparaison of genomes from 8 different 
GBS serotypes 
D.Maione et al, Science 2006 
§  312 surface proteins were cloned 
§  4  Provide a high protective humoral response in 
mouse 
§  Sip and 3 others 
§  The 3 other proteins = « pilus like structures » 
 
	  	  	  	  VACCINE 
54	  	  	  	  	  	  	  	  INTRODUCTION	  &	  BURDEN	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GUIDELINES	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SCREENING	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  VACCINE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CONCLUSION	  ESPID	  10.05.2012	  
GBS « pilus like structure » 
§  Highly immunogenic proteins 
§  Elicit protective and functional antibodies 
§  Virulence factor 
§  Adhesion 
§  Transcytose through cells 
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PROJECT 
 
§  European epidemiology 
§  Genito-rectal colonizing strains  
§  Invasive neonatal strains 
§  Identification of protective levels of 
specific antibodies 
§  Consortium of 8 European 
countries 
§  Development of a vaccine against 
pili proteins & major CPS serotypes 
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CONCLUSION 
Take home messages 
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In Europe, as globally	  
§  Neonatal GBS diseases  
§  EOD and LOD, a public health concern 
§  IAP efficient for prevention of EOD 
§  Best strategy still a matter of debate  
§  Not 100% efficient 
§  No effect on LOD 
§  IAP not widely recommended 
§  Need better data assessing more 
accurately the true burden 
§  GBS vaccine eagerly expected   
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SUMMARY 
§  Culture-based GBS prenatal 
screening 
§  To optimize critical factors 
§  Improved by selective differential 
agars 
§  False +/False - ! 
§  Rapid intrapartum screening 
§  Real time PCR 
§  Yes but costs, logistic, … 
§  Antimicrobial R 
§  Surveillance of Penicillin by NRC 
§  To perform AST for macrolides/clinda 
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Thanks ! 
